THBD and endothelial dysfunction: Patients with HCM exhibit systemic evidence of endothelial dysfunction, as reflected by upregulated circulating levels of soluble thrombomodulin and tissue factor pathway inhibitor, including thrombomodulin and endothelial protein C [59].